Matches in SemOpenAlex for { <https://semopenalex.org/work/W2246215909> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2246215909 abstract "1046 Background: The combination of gemcitabine (G) with paclitaxel (P) has proven efficacy in the first-line treatment of metastatic breast cancer (MBC). In addition, the combination of G with docetaxel (D) has shown activity in several nonrandomized, Phase II, MBC trials. This randomized Phase II trial was conducted to assess the efficacy and safety of G plus P and G plus D combination regimens in previously treated patients with MBC. Methods: Patients with locally advanced or metastatic breast cancer were randomized equally into two groups to receive either GP (G 1,250 mg/m 2 IV on Days 1 and 8 plus P 175 mg/m 2 IV on Day 1) or GD (G 1,000 mg/m 2 IV on Days 1 and 8 plus D 75 mg/m 2 IV on Day 1). Treatment was administered every 21 days and continued until disease progression or undue toxicity. Planned enrollment was 112 patients (56 per group). The primary study objective was tumor response assessed using RECIST criteria. Toxicities were assessed using the NCI Common Toxicity Criteria, Version 2.0. Results: Twenty-five patients were enrolled in each treatment group and accrual was stopped due to slow enrollment. In the GP group, only 23 patients were evaluable for response and 24 patients were monitored for safety. One patient did not receive study medication and was not assessed for efficacy or safety. A second patient was determined to have nonmeasurable disease at baseline and was not assessed for response. Overall response rate was 39% (95% CI 20, 61) for the GP group and 40% (95% CI 21, 61) for the GD group. The median number of cycles administered was 6.5 in the GP group and 6.0 in the GD group. Detailed study results are summarized in the table below. Conclusions: These results show that GP and GD combination regimens are both efficacious in the treatment of MBC, with similar response rates and manageable toxicity profiles. [Table: see text] No significant financial relationships to disclose." @default.
- W2246215909 created "2016-06-24" @default.
- W2246215909 creator A5008174546 @default.
- W2246215909 creator A5008376169 @default.
- W2246215909 creator A5016826271 @default.
- W2246215909 creator A5045876025 @default.
- W2246215909 creator A5086512140 @default.
- W2246215909 creator A5088834594 @default.
- W2246215909 creator A5090221449 @default.
- W2246215909 date "2007-06-20" @default.
- W2246215909 modified "2023-09-27" @default.
- W2246215909 title "Gemcitabine plus paclitaxel and gemcitabine plus docetaxel in first- or second-line metastatic breast cancer: A phase II randomized trial" @default.
- W2246215909 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.1046" @default.
- W2246215909 hasPublicationYear "2007" @default.
- W2246215909 type Work @default.
- W2246215909 sameAs 2246215909 @default.
- W2246215909 citedByCount "3" @default.
- W2246215909 crossrefType "journal-article" @default.
- W2246215909 hasAuthorship W2246215909A5008174546 @default.
- W2246215909 hasAuthorship W2246215909A5008376169 @default.
- W2246215909 hasAuthorship W2246215909A5016826271 @default.
- W2246215909 hasAuthorship W2246215909A5045876025 @default.
- W2246215909 hasAuthorship W2246215909A5086512140 @default.
- W2246215909 hasAuthorship W2246215909A5088834594 @default.
- W2246215909 hasAuthorship W2246215909A5090221449 @default.
- W2246215909 hasConcept C121608353 @default.
- W2246215909 hasConcept C126322002 @default.
- W2246215909 hasConcept C141071460 @default.
- W2246215909 hasConcept C143998085 @default.
- W2246215909 hasConcept C168563851 @default.
- W2246215909 hasConcept C2775930923 @default.
- W2246215909 hasConcept C2777292972 @default.
- W2246215909 hasConcept C2779984678 @default.
- W2246215909 hasConcept C2780258809 @default.
- W2246215909 hasConcept C2781190966 @default.
- W2246215909 hasConcept C29730261 @default.
- W2246215909 hasConcept C31760486 @default.
- W2246215909 hasConcept C530470458 @default.
- W2246215909 hasConcept C71924100 @default.
- W2246215909 hasConcept C90924648 @default.
- W2246215909 hasConceptScore W2246215909C121608353 @default.
- W2246215909 hasConceptScore W2246215909C126322002 @default.
- W2246215909 hasConceptScore W2246215909C141071460 @default.
- W2246215909 hasConceptScore W2246215909C143998085 @default.
- W2246215909 hasConceptScore W2246215909C168563851 @default.
- W2246215909 hasConceptScore W2246215909C2775930923 @default.
- W2246215909 hasConceptScore W2246215909C2777292972 @default.
- W2246215909 hasConceptScore W2246215909C2779984678 @default.
- W2246215909 hasConceptScore W2246215909C2780258809 @default.
- W2246215909 hasConceptScore W2246215909C2781190966 @default.
- W2246215909 hasConceptScore W2246215909C29730261 @default.
- W2246215909 hasConceptScore W2246215909C31760486 @default.
- W2246215909 hasConceptScore W2246215909C530470458 @default.
- W2246215909 hasConceptScore W2246215909C71924100 @default.
- W2246215909 hasConceptScore W2246215909C90924648 @default.
- W2246215909 hasLocation W22462159091 @default.
- W2246215909 hasOpenAccess W2246215909 @default.
- W2246215909 hasPrimaryLocation W22462159091 @default.
- W2246215909 hasRelatedWork W1992476714 @default.
- W2246215909 hasRelatedWork W2084205144 @default.
- W2246215909 hasRelatedWork W2085123446 @default.
- W2246215909 hasRelatedWork W2154590531 @default.
- W2246215909 hasRelatedWork W2246215909 @default.
- W2246215909 hasRelatedWork W2315175766 @default.
- W2246215909 hasRelatedWork W2406160662 @default.
- W2246215909 hasRelatedWork W2508255238 @default.
- W2246215909 hasRelatedWork W2890721774 @default.
- W2246215909 hasRelatedWork W3032651960 @default.
- W2246215909 isParatext "false" @default.
- W2246215909 isRetracted "false" @default.
- W2246215909 magId "2246215909" @default.
- W2246215909 workType "article" @default.